COSCIENS Biopharma Company Top Insiders

COSCIENS Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.1664) % which means that it has lost $0.1664 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1308) %, meaning that it created substantial loss on money invested by shareholders. COSCIENS Biopharma's management efficiency ratios could be used to measure how well COSCIENS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.41. The current Return On Capital Employed is estimated to decrease to -0.89. As of now, COSCIENS Biopharma's Total Current Assets are increasing as compared to previous years. The COSCIENS Biopharma's current Common Stock Shares Outstanding is estimated to increase to about 3.1 MAlmost 89.59 percent of COSCIENS Biopharma outstanding shares are held by general public with 1.48 (percent) owned by insiders and only 8.93 % by other corporate entities. Some institutional investors establish a significant position in stocks such as COSCIENS Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of COSCIENS Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

COSCIENS Biopharma Workforce Comparison

COSCIENS Biopharma Profit Margins

The company has Profit Margin (PM) of (2.0) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.86) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.86.

COSCIENS Biopharma Benchmark Summation

COSCIENS Biopharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as COSCIENS Biopharma often depends on how effective the management is. COSCIENS Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of COSCIENS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the COSCIENS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running COSCIENS Biopharma's price analysis, check to measure COSCIENS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSCIENS Biopharma is operating at the current time. Most of COSCIENS Biopharma's value examination focuses on studying past and present price action to predict the probability of COSCIENS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSCIENS Biopharma's price. Additionally, you may evaluate how the addition of COSCIENS Biopharma to your portfolios can decrease your overall portfolio volatility.